Research letter
Vitiligo under anti–programmed cell death-1 therapy is associated with increased survival in melanoma patients

https://doi.org/10.1016/j.jaad.2019.11.017Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (22)

  • Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

    2021, JAAD International
    Citation Excerpt :

    It was important to avoid a selection bias because patients in whom vitiligo develops may receive the treatment for long enough and live long enough for skin irAEs to develop. These findings are of clinical relevance because the association of vitiligo with increased survival is still debated, mainly due to the low number of patients reported.4-6,14,15 The incidence of vitiligo in patients treated with anti–PD-1 therapies was estimated to be 18.6%, similar to that found in a previous prospective real-life study.5

  • SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the Wnt/β-catenin signaling

    2021, Genes and Diseases
    Citation Excerpt :

    Furthermore, the mRNA and protein expression of SFRP5 was significantly increased in PIG3V cells compared with that in PIG1 cells. Emerging evidences highlight that vitiligo has an inverse relationship with malignant melanoma,52–56 which is consistent with our results. The formation and maturation of melanosomes and the ability to synthesize melanin are key to vitiligo repigmentation.57,58

  • Immunologic adverse events from immune checkpoint therapy

    2020, Best Practice and Research: Clinical Rheumatology
    Citation Excerpt :

    In this setting, successful destruction of tumor cells leads to presentation of tumor-specific and non-specific melanocyte antigens to CD4+ and CD8+ T cells in draining lymph nodes (linked antigen presentation), which, in the presence of continued ICI therapy, generates new T cells responses against the tumor as well as healthy melanocytes [29,34,35]. Consistent with this idea, the development of vitiligo strongly predicts successful anti-melanoma responses [36,37]. A similar mechanism may also link some cases of pneumonitis to anti-tumor responses in patients with NSCLC [38].

View all citing articles on Scopus

Drs Nardin and Jeand'heur contributed equally to this article.

Drs Puzenat and Aubin contributed equally to this article.

Funding sources: None.

Conflicts of interest: Dr Nardin has been a consultant for Novartis, BMS, and MSD. All other authors have no conflicts of interest to declare.

IRB approval status: Reviewed and approved by the Direction de la Recherche Clinique et de l'Innovation (Besançon, France).

View full text